Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
Morris, Gerwyn, Maes, Michael, Berk, Michael et al. · Metabolic brain disease · 2019 · DOI
Quick Summary
This study proposes a theory for how ME/CFS might develop, starting with an infection that triggers lasting problems in the body's immune system and stress response. The authors suggest that in genetically vulnerable people, this leads to a chain of events: increased inflammation, intestinal problems that allow bacteria-related substances to enter the bloodstream, nervous system dysfunction, and eventually a state where the immune system becomes exhausted and less able to fight back. This model tries to explain why ME/CFS patients have the specific symptoms and lab abnormalities doctors observe.
Why It Matters
Understanding how ME/CFS develops is essential for identifying potential treatment targets and biomarkers. This comprehensive mechanistic model connects multiple known abnormalities in ME/CFS patients into a coherent biological narrative, providing a testable framework that could guide future research into prevention and therapeutic interventions. For patients, a validated disease mechanism could improve medical recognition and lead to more effective treatments.
Observed Findings
Literature indicates ME/CFS patients show chronic inflammatory and oxidative stress markers
Evidence documents neuroinflammation and neurocognitive abnormalities in ME/CFS cohorts
Studies have identified dysautonomia and mitochondrial performance impairment in patient populations
Research demonstrates markers of immune regulation including altered T cell and macrophage function
Increased intestinal permeability has been reported in some ME/CFS patients
Inferred Conclusions
Post-infection triggering of DAMPs in genetically predisposed individuals initiates a cascade of chronic inflammation and oxidative stress that characterizes ME/CFS
Immune exhaustion and metabolic downregulation via endotoxin tolerance mechanisms can explain the sustained symptom profile and immune abnormalities observed in ME/CFS
Dysautonomia, neuroinflammation, and mitochondrial dysfunction are interconnected consequences of chronic immune activation and stress rather than independent pathologies
Remaining Questions
Which specific genetic factors confer susceptibility to chronic post-infection immune dysregulation in ME/CFS?
What precipitating infections or infection characteristics most reliably trigger this disease pathway?
What This Study Does Not Prove
This is a theoretical model based on integrating existing literature rather than new experimental data, so it does not definitively prove the proposed sequence of events occurs in ME/CFS patients. The model does not establish causation for individual mechanisms and cannot prove that endotoxin tolerance is the primary driver of ME/CFS rather than a secondary consequence. Validation would require prospective clinical studies tracking patients at each proposed disease stage.
Can endotoxin tolerance be reversed therapeutically, and would reversal restore normal immune and metabolic function?
How do individual ME/CFS patients vary in which mechanism (neuroinflammation, mitochondrial dysfunction, dysautonomia) predominates, and does this variation predict treatment response?